About
Our journey
Key milestones on our journey
Abcam was established in 1998 by Jonathan Milner, David Cleevely and Tony Kouzarides in Cambridge, UK. Their mission was to source and sell online the best research antibodies in the world, together with the most comprehensive data, fast delivery, helpful customer service and technical support.
Today, with over 20 years of experiences, facilities in Europe, USA and Asia and customers in over 130 countries, we are a leading global proteomics pioneer that identifies, develops, and manufactures quality biological, protein, and custom cell engineering tools to the life science research and clinical communities.
2018
Agreement signed with Roche covering Spring Bioscience portfolio of over 750 products
Number of recombinant RabMAb antibodies available surpasses 13,000
2019
Calico Biolabs acquired (custom rabbit monoclonal antibody) capabilities
EdiGene acquired (cell line and lysate portfolio
2020
Cancer Research UK – custom partnership to accelerate cancer research
Marker Gene Technologies acquired (biology and organic chemistry)
Applied StemCell acquired (cell engineering and gene editing)
Expedeon acquired proteomics and immunology (conjugation)
2020
2020
Number of recombinant antibodies surpasses 20,000
2020
Cancer Research UK - custom partnership to accelerate cancer research
2020
Applied StemCell acquired (cell engineering and gene editing)
2020
Proteomics and immunology businesses of Expedeon acquired (conjugation)
2020
Marker Gene Technologies acquired (biology and organic chemistry)
2018
Calico Biolabs acquired (custom rabbit monoclonal antibody capabilities)
2018
EdiGene’s cell lines and lysates portfolio acquired (engineered cell lines)
2018
Agreement signed with Roche covering Spring Bioscience portfolio of over 750 products
2018
Number of recombinant RabMAb antibodies surpasses 13,000
2017
Annual revenues surpass £200m
(£217.1m for FY2016/17)
2015
Firefly BioWorks acquired
Adding multiplex and MiRNA assay capabilities
2015
AxioMx acquired
Proving in vitro recombinant monoclonal antibody capabilities (phage display)
2014
Customer-focused growth strategy initiated
2014
Alan Hirzel appointed as CEO
2013
Annual revenues surpass £100m
(£122.2m for FY2012/13)
2013
Chinese office in Shanghai opened
2011
Ascent Scientific Ltd acquired
Enhancing Abcam’s offering in high-performance biochemicals
2011
MitoSciences acquired
Bringing immunoassay capabilities in-house
2005
2005
Sales of £12.1 million (2004/5)
2003
First overseas office Opened in Cambridge, MA
1998
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
abcam.comabcam.co.jp
abcam.cn
© Abcam plc. all rights reserved.
Abcam plc is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds. Static content was last updated on 09 Nov 2020.
Website by FisherPaul